乳腺癌病人血清HER-2/neu检测及其临床意义

【目的】本研究分析晚期乳腺癌患者血清HER-2／neu的水平与预后的关系，并探讨其临床意义。【方法】酶联免疫法（ELISA）检测94例晚期乳腺癌患者血清HER-2／neu的浓度．分析血清与组织中HER-2／neu表达的相关性，并分析其与患者预后的关系。【结果】94例晚期乳腺癌患者就诊时的血清HER-2／neu浓度为0．34-275．25μg／L（平均浓度为23．69μg／L）。血清HER-2／neu浓度的高低与化疗的有效性、疾病进展时间的长短无关。晚期乳腺癌患者的血清HER-2／neu浓度与肿瘤组织中HER-2／neu表达强阳性是一致的。【结论】血清HER-2／neu尚不能确立为独立的预后指标，需要更多的病例进行分析

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements

Determination of the number of ψ(3686) events taken at BESIII

The number of ψ(3686) events collected by the BESIII detector during the 2021 run period is determined to be (2259.3±11.1)×106 by counting inclusive ψ(3686) hadronic events. The uncertainty is systematic and the statistical uncertainty is negligible. Meanwhile, the numbers of ψ(3686) events collected during the 2009 and 2012 run periods are updated to be (107.7±0.6)×106 and (345.4±2.6)×106, respectively. Both numbers are consistent with the previous measurements within one standard deviation. The total number of ψ(3686) events in the three data samples is (2712.4±14.3)×10^